生物技术公司Septerna宣布其口服Mrgprx2靶向药物SEP-631在治疗肥大细胞驱动疾病的1期临床试验中获得积极数据。该药物展现出良好的安全性和耐受性特征,为后续临床开发奠定基础。公司同时公布了针对该候选药物的初步2期临床试验战略规划,标志着其向解决免疫炎症疾病迈出关键一步。
生物技术公司Septerna宣布其口服Mrgprx2靶向药物SEP-631在治疗肥大细胞驱动疾病的1期临床试验中获得积极数据。该药物展现出良好的安全性和耐受性特征,为后续临床开发奠定基础。公司同时公布了针对该候选药物的初步2期临床试验战略规划,标志着其向解决免疫炎症疾病迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.